Alnylam Pharmaceuticals CEO John Maraganore's 2021 pay jumps 30% to $10M
Alnylam Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 5, 2022
Alnylam Pharmaceuticals reported fiscal year 2021 executive compensation information on April 5, 2022.
In 2021, five executives at Alnylam Pharmaceuticals received on average a compensation package of $6.8M, a 40% increase compared to previous year.
Average pay of disclosed executives at Alnylam Pharmaceuticals
John M. Maraganore, Chief Executive Officer, received $10M in total, which increased by 30% compared to 2020. 77% of Maraganore's compensation, or $7.9M, was in option awards. Maraganore also received $1.1M in non-equity incentive plan, $949K in salary, as well as $271K in other compensation.
For fiscal year 2021, the median employee pay was $231,163 at Alnylam Pharmaceuticals. Therefore, the ratio of John M. Maraganore's pay to the median employee pay was 44 to one.
Yvonne L. Greenstreet, Chief Operating Officer, received a compensation package of $8.6M, which increased by 183% compared to previous year. 86% of the compensation package, or $7.3M, was in option awards.
Tolga Tanguler, Executive Vice President, Chief Commercial Officer, earned $6.9M in 2021.
Akshay K. Vaishnaw, President, Research and Development, received $5.4M in 2021, which increases by 87% compared to 2020.
Jeffrey V. Poulton, Chief Financial Officer, earned $2.8M in 2021, a 12% increase compared to previous year.
Related executives
John Maraganore
Alnylam Pharmaceuticals
Chief Executive Officer
Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Operating Officer
Akshay Vaishnaw
Alnylam Pharmaceuticals
President, Research and Development
Jeffrey Poulton
Alnylam Pharmaceuticals
Chief Financial Officer
Tolga Tanguler
Alnylam Pharmaceuticals
Executive Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on April 5, 2022.